Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models

To assess the therapeutic outcome of selective block of VEGFR1, we have evaluated the activity of a new specific antagonist of VEGFR1, named iVR1 (inhibitor of VEGFR1), in syngenic and xenograft colorectal cancer models, in an artificial model of metastatization, and in laser-induced choroid neovascularization. iVR1 inhibited tumor growth and neoangiogenesis in both models of colorectal cancer, with an extent similar to that of bevacizumab, a monoclonal antibody anti-VEGF-A. It potently inhibited VEGFR1 phosphorylation in vivo, determining a strong inhibition of the recruitment of monocyte-macrophages and of mural cells as confirmed, in vitro, by the ability to inhibit macrophages migration. iVR1 was able to synergize with irinotecan determining a shrinkage of tumors that became undetectable after three weeks of combined treatment. Such treatment induced a significant prolongation of survival similar to that observed with bevacizumab and irinotecan combination. iVR1 also fully prevented lung invasion by HCT-116 cells injected in mouse tail vein. Also, iVR1 impressively inhibited choroid neovascularization after a single intravitreal injection. Collectively, data showed the strong potential of iVR1 peptide as a new anti-tumor and anti-metastatic agent and demonstrate the high flexibility of VEGFR1 antagonists as therapeutic anti-angiogenic agents in different pathological contexts.

[1]  C. Boni,et al.  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.

[2]  M. Reille‐Seroussi,et al.  Design and Synthesis of C-Terminal Modified Cyclic Peptides as VEGFR1 Antagonists , 2014, Molecules.

[3]  R. Bianco,et al.  Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models , 2014, Breast Cancer Research.

[4]  S. De Falco.  Antiangiogenesis therapy: an update after the first decade , 2014, The Korean journal of internal medicine.

[5]  Kang Zhang,et al.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.

[6]  J. Pollard,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[7]  Liangfang Shen,et al.  Antiangiogenic and Antitumoral Effects Mediated by a Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1)-Targeted DNAzyme , 2013, Molecular Medicine.

[8]  P. Carmeliet,et al.  PlGF: a multitasking cytokine with disease-restricted activity. , 2012, Cold Spring Harbor perspectives in medicine.

[9]  Sylvain Rault,et al.  Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening. , 2011, Chemistry & biology.

[10]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[11]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[12]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[13]  M. Squadrito,et al.  Macrophage regulation of tumor angiogenesis: implications for cancer therapy. , 2011, Molecular aspects of medicine.

[14]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[15]  M. Shibuya,et al.  Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. , 2010, Cancer research.

[16]  A. Orlandi,et al.  A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. , 2010, Cancer research.

[17]  Yan Wu,et al.  Vascular endothelial growth factor receptor‐1 in human cancer , 2010, Cancer.

[18]  R. Jain,et al.  VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation , 2009, PloS one.

[19]  Yihai Cao.  Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.

[20]  J. Ambati,et al.  Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1* , 2008, Journal of Biological Chemistry.

[21]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[22]  M. Shibuya,et al.  Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase , 2008, Japanese Journal of Ophthalmology.

[23]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[24]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[25]  Alice P. Taylor,et al.  Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts , 2007, Molecular Cancer Therapeutics.

[26]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[27]  D. Hicklin,et al.  Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer , 2006, Clinical Cancer Research.

[28]  M. Shibuya,et al.  Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. , 2006, Blood.

[29]  J. Ambati,et al.  Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. , 2006, The Journal of clinical investigation.

[30]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[31]  A. Parenti,et al.  Intracellular pathways triggered by the selective FLT‐1‐agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia , 2005, British journal of pharmacology.

[32]  Ge Li,et al.  Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1–Specific Hexapeptide, Inhibits Tumor Growth and Metastasis , 2005, Clinical Cancer Research.

[33]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[34]  P. Oettgen,et al.  Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids , 2003, Current Biology.

[35]  M. Shibuya,et al.  MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.

[36]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[37]  T. Noda,et al.  Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.

[38]  S. Grimm,et al.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Breier,et al.  The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities , 1996, The Journal of Biological Chemistry.

[41]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[42]  W. Scheuer,et al.  Quantification of human Alu sequences by real-time PCR – an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants , 2004, Clinical & Experimental Metastasis.

[43]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.